Botulism (Clostridium botulinum)

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 2763-2767.e2

  Hodowanec, Aimee ^a   Bleck, Thomas P ^a,b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

Author keywords

Anaerobic infection; Bioterrorism; Botulism; Clostridial infections; Foodborne illness; Heptavalent botulinum antitoxin; Human botulinum antitoxin; Infant botulism; Paralysis; Toxin; Wound botulism

Indexed keywords

EID: 84924463482     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00247-2     Document Type: Chapter

References (135)

1. Hatheway CL Bacterial sources of clostridial neurotoxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 4-25. Academic Press, San Diego, CA. L.L. Simpson (Ed.).
2. Oguma K, Yokota K, Hayashi S, et al. Infant botulism due to Clostridium botulinum type C toxin. Lancet 1990, 336:1449-1450.
3. Kerner J Neue Beobachtungen über die in Würtemburgso haüfig vorfallen Vergiftung durch den Genuss gerauchter Würst 1820, Tubingen.
4. Young JH Botulism and the ripe olive scare of 1919-1920. Bull Hist Med 1976, 50:372-391.
5. van Ermengen E Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus. Z Hyg Infektionskrankh 1897, 26:1-56.
6. Landman G Ueber die Ursache der Darmstadter Bohnen Vergiftung. Hyg Rundsch 1904, 14:449-452.
7. Davis JB, Mattman LH, Wiley M Clostridium botulinum in a fatal wound infection. JAMA 1951, 146:646-648.
8. Midura TF, Arnon SS Infant botulism: identification of Clostridium botulinum and its toxin in faeces. Lancet 1976, 2:934-936.
9. Chia JK, Clark JB, Ryan CA, et al. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986, 315:239-241.
10. Lamanna C, McElroy OE, Eklund HW The purification and crystallization of Clostridium botulinum type A toxin. Science 1946, 103:613-614.
11. Shaffer N, Wainwright RB, Middaugh JP, et al. Botulism among Alaska Natives: the role of changing food preparation and consumption practices. West J Med 1990, 153:390-393.
12. Gao QY, Huang YF, Wu JG, et al. A review of botulism in China. Biomed Environ Sci 1990, 3:326-336.
13. Sheth AN, Wiersma P, Atrubin D, et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. Clin Infect Dis 2008, 47:1245-1251.
14. Centers for Disease Control and Prevention Botulism associated with commercially canned chili sauce: Texas and Indiana, July 2007. MMWR Morb Mortal Wkly Rep 2007, 56:767-769.
15. Hashimoto H, Clyde VJ, Parko KL Botulism from peyote. N Engl J Med 1998, 339:203-204.
16. Sobel J, Tucker N, Sulka A, et al. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004, 10:1606-1611.
17. Centers for Disease Control and Prevention (CDC) Botulism Annual Summary, 2010 2011, U.S. Department of Health and Human Services, CDC, Atlanta.
18. Barash JR, Arnon SS A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014, 209:183-191.
19. Midura TF, Snowden S, Wood RM, et al. Isolation of Clostridium botulinum from honey. J Clin Microbiol 1979, 9:282-283.
20. Spika JS, Shaffer N, Hargrett-Bean N, et al. Infant botulism in the United States: an epidemiologic study of cases occurring outside of California. Am J Public Health 1983, 73:1385-1388.
21. Arnon S Infant botulism. Textbook of Pediatric Infectious Diseases 1998, 1570-1577. Saunders, Philadelphia. 4th ed. R.D. Feigen, J.D. Cherry (Eds.).
22. Koepke R, Sobel J, Arnon SS Global occurrence of infant botulism, 1976-2006. Pediatrics 2008, 122:e73-e82.
23. Hurst DL, Marsh WW Early severe infantile botulism. J Pediatr 1993, 122:909-911.
24. Gimenez JA, Gimenez MA, DasGupta BR Characterization of the neurotoxin isolated from a Clostridium baratii strain implicated in infant botulism. Infect Immun 1992, 60:518-522.
25. Suen JC, Hatheway CL, Steigerwalt AG, et al. Genetic confirmation of the identities of neurotoxigenic Clostridium baratii and Clostridium butyricum implicated as agents of human botulism. J Clin Microbiol 1988, 26:2191-2192.
26. Werner SB, Passaro DJ, McGee J, et al. Wound botulism in California, 1951-1998: a recent epidemic in heroin injectors. Clin Infect Dis 2000, 31:1018-1024.
27. Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998, 279:859-863.
28. Kalka-Moll WM, Aurbach U, Schaumann R, et al. Wound botulism in injection drug users. Emerg Infect Dis 2007, 13:942-943.
29. Brett MM, Hallas G, Mpamugo O Wound botulism in the UK and Ireland. J Med Microbiol 2004, 53:555-561.
30. Update zu einer Haufung von Wundbotulismus bei injizierenden Dregenkonsumenten in Nordrhein-Westfalen Epidemiologisches Bulletin 2005, Robert Koch Institut, Berlin.
31. MacDonald KL, Cohen ML, Blake PA The changing epidemiology of adult botulism in the United States. Am J Epidemiol 1986, 124:794-799.
32. Chia JK, Clark JB, Ryan CA, et al. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986, 315:239-241.
33. Fenicia L, Franciosa G, Pourshaban M, et al. Intestinal toxemia botulism in two young people, caused by Clostridium butyricum type E. Clin Infect Dis 1999, 29:1381-1387.
34. Griffin PM, Hatheway CL, Rosenbaum RB, et al. Endogenous antibody production to botulinum toxin in an adult with intestinal colonization botulism and underlying Crohn's disease. J Infect Dis 1997, 175:633-637.
35. McCroskey LM, Hatheway CL, Woodruff BA, et al. Type F botulism due to neurotoxigenic Clostridium baratii from an unknown source in an adult. J Clin Microbiol 1991, 29:2618-2620.
36. Crowner BE, Brunstrom JE, Racette BA Iatrogenic botulism due to therapeutic botulinum toxin A injection in a pediatric patient. Clin Neuropharmacol 2007, 30:310-313.
37. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006, 296:2476-2479.
38. Souayah N, Karim H, Kamin SS, et al. Severe botulism after focal injection of botulinum toxin. Neurology 2006, 67:1855-1856.
39. Roblot F, Popoff M, Carlier JP, et al. Botulism in patients who inhale cocaine: the first cases in France. Clin Infect Dis 2006, 43:e51-e52.
40. M'ikantha NM, Southwell B, Lautenbach E Automated laboratory reporting of infectious diseases in a climate of bioterrorism. Emerg Infect Dis 2003, 9:1053-1057.
41. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
42. Cato EP, George WL, Finegold SM Genus Clostridium praemozski 1880, 23AL. Bergey's Manual of Systematic Bacteriology 1986, Vol 2:1141-1200. Williams & Wilkins, Baltimore.
43. Eklund MW, Poysky FT, Habig WH Bacteriophages and plasmids in Clostridium botulinum and Clostridium tetani and their relationship to the production of toxin. Botulinum Neurotoxin and Tetanus Toxin 1989, 25-51. Academic Press, San Diego, CA. L.L. Simpson (Ed.).
44. Hauschild AHW Clostridium botulinum. Foodborne Bacterial Pathogens 1989, 112-189. Marcel Dekker, New York. M.P. Doyle (Ed.).
45. Tacket CO, Rogawski MA Botulism. Botulinum Neurotoxin and Tetanus Toxin 1989, 351-378. Academic Press, San Diego, CA. L.L. Simpson (Ed.).
46. Schreiner MS, Field E, Ruddy R Infant botulism: a review of 12 years experience at the Children's Hospital of Philadelphia. Pediatrics 1991, 87:159-165.
47. Park JB, Simpson LL Inhalational poisoning by botulinum toxin and inhalation vaccination with its heavy-chain component. Infect Immun 2003, 71:1147-1154.
48. Fu FN, Lomneth RB, Cai S, et al. Role of zinc in the structure and toxic activity of botulinum neurotoxin. Biochemistry 1998, 37:5267-5278.
49. Critchley EMR, Mitchell JD Human botulism. Br J Hosp Med 1992, 43:290-292.
50. Simpson LL Kinetic studies on the interaction between botulinum toxin type A and the cholinergic neuromuscular junction. J Pharmacol Exp Ther 1980, 212:16-21.
51. Black JD, Dolly JO Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves. J Cell Biol 1986, 103:521-534.
52. Black JD, Dolly JO Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. II. Autoradiographic evidence for its uptake into motor nerves by receptor-mediated endocytosis. J Cell Biol 1986, 103:535-544.
53. Simpson LL Peripheral actions of the botulinum toxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 153-178. Academic Press, San Diego. L.L. Simpson (Ed.).
54. Bleck TP, Brauner JS Tetanus. Infections of the Central Nervous System 2004, 625-648. Lippincott Williams and Wilkins, New York. 3rd ed. W.M. Scheld, R.J. Whitley, C.M. Marra (Eds.).
55. Trimble WS, Cowan D, Scheller RH VAMP-1: a synaptic vesicle associated integral membrane protein. Proc Natl Acad Sci U S A 1988, 85:4538-4542.
56. McMahon HT, Ushkaryov YA, Edelmann L, et al. Cellubrevin is a ubiquitous tetanus-toxin substrate homologous to a putative synaptic vesicle fusion protein. Nature 1993, 364:346-349.
57. Buckley KM, Floor E, Kelly RB Cloning and sequence analysis of cDNA encoding p38, a major synaptic vesicle protein. J Cell Biol 1987, 105:2447-2456.
58. Blasi J, Binz T, Yamasaki S, et al. Inhibition of neurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins. J Physiol (Paris) 1994, 88:235-241.
59. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
60. Nowakowski JL, Courtney BC, Bing QA, et al. Production of an expression system for a synaptobrevin fragment to monitor cleavage by botulinum neurotoxin B. J Protein Chem 1998, 17:453-462.
61. Foran P, Shone CC, Dolly JO Differences in the protease activities of tetanus and botulinum B toxins revealed by the cleavage of vesicle-associated membrane protein and various sized fragments. Biochemistry 1994, 33:15365-15374.
62. Lacy DB, Tepp W, Cohen AC, et al. Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat Struct Biol 1998, 5:898-902.
63. Sciavo G, Santussi A, Dasgupta BR, et al. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett 1993, 335:99-103.
64. Hayashi T, McMahon H, Yamasaki S, et al. Synaptic vesicle membrane fusion complex: action of clostridial neurotoxins on assembly. EMBO J 1994, 13:5051-5061.
65. Hausinger A, Volknandt W, Zimmerman H Calcium-dependent endogenous proteolysis of the vesicle proteins synaptobrevin and synaptotagmin. Neuroreport 1995, 6:637-641.
66. Meunier FA, Schiavo G, Molgo J Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol (Paris) 2002, 96:1013-1015.
67. Billante CR, Zealear DL, Billante M, et al. Comparison of neuromuscular blockade and recovery with botulinum toxins A and F. Muscle Nerve 2002, 26:395-403.
68. Jones S, Huma Z, Haugh C, et al. Central nervous system involvement in infantile botulism. Lancet 1990, 335:228.
69. Terranova W, Palumbo JN, Berman JG Ocular findings in botulism type B. JAMA 1979, 241:475-477.
70. Friedman DI, Fortanasce VN, Sadun AA Tonic pupils as a result of botulism. Am J Ophthalmol 1990, 109:236-237.
71. Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B foodborne botulism. Ann Intern Med 1981, 95:442-445.
72. Colerbatch JG, Wolff AH, Gilbert RJ, et al. Slow recovery from severe foodborne botulism. Lancet 1989, 2:1216-1217.
73. Vita G, Girlanda P, Puglisi RM, et al. Cardiovascular-reflex testing and single-fiber electromyography in botulism: a longitudinal study. Arch Neurol 1987, 44:202-206.
74. Hughes JM Botulism. Infections of the Central Nervous System 1991, 589-602. Raven Press, New York. W.M. Scheld, R.J. Whitley, D.T. Durack (Eds.).
75. Cornblath DR, Sladky JT, Sumner AJ Clinical electro-physiology of infantile botulism. Muscle Nerve 1983, 6:448-452.
76. Oken A, Barnes S, Rock P, et al. Upper airway obstruction and infant botulism. Anesth Analg 1992, 75:136-138.
77. Angulo FJ, Getz J, Taylor JP, et al. A large outbreak of botulism: the hazardous baked potato. J Infect Dis 1998, 178:172-177.
78. Glauser TA, Maquire HC, Sladky JT Relapse of infant botulism. Ann Neurol 1990, 28:187-189.
79. Elston HR, Wang M, Loo LK Arm abscesses caused by Clostridium botulinum. J Clin Microbiol 1991, 29:2379-2678.
80. Kudrow DB, Henry DA, Haake DA, et al. Botulism associated with Clostridium botulinum sinusitis after intranasal cocaine abuse. Ann Intern Med 1988, 109:984-985.
81. Schantz EJ, Johnson EA Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 1997, 40:317.
82. Edell TA, Sullivan CP, Osborn KM, et al. Wound botulism associated with a positive Tensilon test. West J Med 1983, 139:218-219.
83. Cherington M Botulism. Semin Neurol 1990, 10:27-31.
84. Dunbar EM Botulism. J Infect 1990, 20:1-3.
85. Notermans S, Nagel J Assays for botulinum and tetanus toxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 319-331. Academic Press, San Diego, CA. L.L. Simpson (Ed.).
86. Dowell VR, McCroskey LM, Hatheway CL, et al. Coproexamination for botulinal toxin and Clostridium botulinum: a new procedure for laboratory diagnosis of botulism. JAMA 1977, 238:1829-1832.
87. Roman MG, Humber JY, Hall PA, et al. Amplified immunoassay ELISA-ELCA for measuring Clostridium botulinum type E neurotoxin in fish fillets. J Food Prot 1994, 57:985-990.
88. Shone CC, Wilton-Smith P, Appleton N, et al. Monoclonal antibody-based immunoassay for type A Clostridium botulinum toxin is comparable to the mouse bioassay. Appl Environ Microbiol 1985, 50:63-67.
89. Zhang Y, Lou J, Jenko K, et al. Simultaneous and sen-sitive detection of six serotypes of botulinum neurotoxin using enzyme-linked immunosorbent assay-based protein antibody microarrays. Anal Biochem 2012, 430:185-192.
90. Rodriguez A, Dezfulian M Rapid identification of Clostridium botulinum and botulinal toxin in food. Folia Microbiol 1997, 42:149-151.
91. Lindstrom M, Korleala H Laboratory diagnosis of botulism. Clin Microbiol Rev 2006, 19:298-314.
92. Satterfield BA, Stewart AF, Lew CS, et al. A quadruplex real-time PCR assay for rapid detection and differentiation of the Clostridium botulinum toxin genes A, B, E and F. J Med Microbiol 2010, 59:55-64.
93. Mazuet C, Ezan E, Volland H, et al. Toxin detection in patient's sera by mass spectrometry during two outbreaks of type A botulism in France. J Clin Microbiol 2012, 50:4091-4094.
94. Cherington M Electrophysiologic methods as an aid in diagnosis of botulism: a review. Muscle Nerve 1982, 6:528-529.
95. Gutmann L, Pratt L Pathophysiologic aspects of human botulism. Arch Neurol 1976, 33:175-179.
96. Graf W, Hays RM, Astley SJ, et al. Electrodiagnosis reliability in the diagnosis of infant botulism. J Pediatr 1992, 120:747-749.
97. Buchman AS, Comella CL, Stebbins GT, et al. Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol 1993, 16:205-210.
98. Barrett DH Endemic food-borne botulism: clinical experience, 1973-1986. Alaska Med 1991, 33:101-108.
99. Centers for Disease Control and Prevention Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 2010, 59:299.
100. Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006, 354:462-471.
101. Underwood K, Rubin S, Deakers T, et al. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Children's Hospital Los Angeles. Pediatrics 2007, 120:e1380-e1385.
102. Wilson R, Morris JG, Snyder JD, et al. Clinical characteristics of infant botulism in the United States: a study of the non-California cases. Pediatr Infect Dis 1982, 1:148-150.
103. Centers for Disease Control and Prevention Botulism in the United States 1899-1996: Handbook for Epidemiologists, Clinicians, and Laboratory Workers (draft) 1998, Centers for Disease Control and Prevention, Atlanta.
104. Wilcox PG, Morrison NJ, Pardy RL Recovery of the ventilatory and upper airway muscles and exercise performance after type A botulism. Chest 1990, 98:620-626.
105. Gottlieb SL, Kretsinger K, Tarkhashvili N, et al. Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis 2007, 45:174-180.
106. Beller M, Middaugh JP Repeated type E botulism in an Alaskan Eskimo. N Engl J Med 1990, 322:855.
107. Siegel LS Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay. J Clin Microbiol 1988, 26:2351-2356.
108. Centers for Disease Control and Prevention Notice of CDC's discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR Morb Mortal Wkly Rep 2011, 60:1454-1455.
109. Shearer JD, Manetz TS, House RV Preclinical safety assessment of recombinant botulinum vaccine A/B (rBV A/B). Vaccine 2012, 30:1917-1926.
110. Oguma K, Yokota K, Hayashi S, et al. Infant botulism due to Clostridium botulinum type C toxin. Lancet 1990, 336:1449-1450.
111. Davis JB, Mattman LH, Wiley M Clostridium botulinum in a fatal wound infection. JAMA 1951, 146:646-648.
112. Chia JK, Clark JB, Ryan CA, et al. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986, 315:239-241.
113. Sobel J, Tucker N, Sulka A, et al. Foodborne botulism in the United States, 1990-2000. Emerg Infect Dis 2004, 10:1606-1611.
114. Centers for Disease Control and Prevention (CDC) Botulism Annual Summary, 2010 2011, U.S. Department of Health and Human Services, CDC, Atlanta.
115. Barash JR, Arnon SS A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis 2014, 209:183-191.
116. Midura TF, Snowden S, Wood RM, et al. Isolation of Clostridium botulinum from honey. J Clin Microbiol 1979, 9:282-283.
117. Arnon S Infant botulism. Textbook of Pediatric Infectious Diseases 1998, 1570-1577. Saunders, Philadelphia. 4th ed. R.D. Feigen, J.D. Cherry (Eds.).
118. Koepke R, Sobel J, Arnon SS Global occurrence of infant botulism, 1976-2006. Pediatrics 2008, 122:e73-e82.
119. Werner SB, Passaro DJ, McGee J, et al. Wound botulism in California, 1951-1998: a recent epidemic in heroin injectors. Clin Infect Dis 2000, 31:1018-1024.
120. Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998, 279:859-863.
121. Chia JK, Clark JB, Ryan CA, et al. Botulism in an adult associated with food-borne intestinal infection with Clostridium botulinum. N Engl J Med 1986, 315:239-241.
122. Chertow DS, Tan ET, Maslanka SE, et al. Botulism in 4 adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA 2006, 296:2476-2479.
123. Arnon SS, Schechter R, Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001, 285:1059-1070.
124. Schreiner MS, Field E, Ruddy R Infant botulism: a review of 12 years experience at the Children's Hospital of Philadelphia. Pediatrics 1991, 87:159-165.
125. Simpson LL Peripheral actions of the botulinum toxins. Botulinum Neurotoxin and Tetanus Toxin 1989, 153-178. Academic Press, San Diego. L.L. Simpson (Ed.).
126. Bleck TP, Brauner JS Tetanus. Infections of the Central Nervous System 2004, 625-648. Lippincott Williams and Wilkins, New York. 3rd ed. W.M. Scheld, R.J. Whitley, C.M. Marra (Eds.).
127. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992, 359:832-835.
128. Jones S, Huma Z, Haugh C, et al. Central nervous system involvement in infantile botulism. Lancet 1990, 335:228.
129. Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B foodborne botulism. Ann Intern Med 1981, 95:442-445.
130. Lindstrom M, Korleala H Laboratory diagnosis of botulism. Clin Microbiol Rev 2006, 19:298-314.
131. Graf W, Hays RM, Astley SJ, et al. Electrodiagnosis reliability in the diagnosis of infant botulism. J Pediatr 1992, 120:747-749.
132. Centers for Disease Control and Prevention Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR Morb Mortal Wkly Rep 2010, 59:299.
133. Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med 2006, 354:462-471.
134. Underwood K, Rubin S, Deakers T, et al. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Children's Hospital Los Angeles. Pediatrics 2007, 120:e1380-e1385.
135. Centers for Disease Control and Prevention Botulism in the United States 1899-1996: Handbook for Epidemiologists, Clinicians, and Laboratory Workers (draft) 1998, Centers for Disease Control and Prevention, Atlanta.